Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: An analysis of ACCENT adjuvant trials

Journal of the National Cancer Institute

Volumn 103, Issue 20, 2011, Pages 1498-1506

  Yothers, Greg ^a,b   Sargent, Daniel J ^c,j   Wolmark, Norman ^d   Goldberg, Richard M ^e,k   O'Connell, Michael J ^a   Benedetti, Jacqueline K ^f,l   Saltz, Leonard B ^g,k   Dignam, James J ^a,h,m   Blackstock, A William ^i,k  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

^j North Central Cancer Treatment Group Rochester   (United States)

^k Cancer and Leukemia Group B   (United States)

^l Southwest Oncology Group   (United States)

^m Radiation Therapy Oncology Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; SEMUSTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE INTERVAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AFRICAN AMERICANS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; COLONIC NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUOROURACIL; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LEVAMISOLE; LOMUSTINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UNITED STATES; VINCRISTINE;

EID: 80054941039     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr310     Document Type: Article

References (31)

1. Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2008. http://seer.cancer.gov/csr/1975-2006/. Accessed June 1, 2010. Based on November 2008 SEER data submission, posted to the SEER web site, 2009.
2. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am. 2005;89(4):771-793. (Pubitemid 40755543)
3. Sanoff H, Sargent DJ, Green EM, McLeod HM, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009;27(25):4109-4115.
4. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456-3461. (Pubitemid 47310883)
5. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352-358. (Pubitemid 20042739)
6. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16(1):295-300. (Pubitemid 28041612)
7. O'Connell MJ, Sargent DJ, Windschitl HE, et al. Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Clin Colorectal Cancer. 2006;6(2):133-139. (Pubitemid 44445748)
8. Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol. 2005;23(9):1819-1825. (Pubitemid 46211360)
9. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988;80(1):30-36. (Pubitemid 18076566)
10. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol. 1990;8:1466-1475. (Pubitemid 20301177)
11. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from NSABP protocol C-03. J Clin Oncol. 1993;11:1879-1887. (Pubitemid 23304611)
12. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17(11):3553-3559. (Pubitemid 29517927)
13. Wolmark N, Bryant J, Smith R, et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst. 1998;90(23):1810-1816. (Pubitemid 28559893)
14. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil-tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24(13):2059-2064. (Pubitemid 46622115)
15. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP protocol C-07. J Clin Oncol. 2007;25(16):2198-2204. (Pubitemid 46954643)
16. Public Law 103-43. National Institutes of Health Revitalization Act of 1993. 42 USC 289 (a)(1). http://history.nih.gov/research/downloads/PL103-43.pdf. Accessed June 13, 2011.
17. Dignam JJ, Colangelo L, Tian W, et al. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. 1999;91(22):1933-1940.
18. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002;94(15):1160-1167. (Pubitemid 34919053)
19. Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972;34(2):187-220.
20. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
21. Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005;24(20):3089-3110. (Pubitemid 41489423)
22. Harper S, Lynch J, Burris S, Davey Smith G. Trends in the black-white life expectancy gap in the United States, 1983-2003. JAMA. 2007;297(11):1224- 1232. (Pubitemid 46465730)
23. Howard J, Hankey BF, Greenberg RS, et al. A collaborative study of differences in the survival rates of black patients and white patients with cancer. Cancer. 1992;69(9):2349-2360.
24. Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994;272(12):947-954.
25. Mayberry RM, Coates RJ, Hill HA, et al. Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst. 1995;87(22):1686-1693.
26. Hill HA, Eley JW, Harlan LC, Greenberg RS, Barrett RJ II, Chen VW. Racial differences in endometrial cancer survival: the Black/White Cancer Survival Study. Obstet Gynecol. 1996;88(6):919-926. (Pubitemid 26391490)
27. Chen VW, Fenoglio-Preiser CM, Wu XC, et al. Aggressiveness of colon carcinoma in blacks and whites. National Cancer Institute Black/White Cancer Survival Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6(12):1087-1093. (Pubitemid 28007422)
28. Etienne MC, Formento JL, Chazal M, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics. 2004;14(12):785-792. (Pubitemid 40054334)
29. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43(6):1011-1016. (Pubitemid 46483039)
30. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res. 2006;12(18):5491-5495. (Pubitemid 44497265)
31. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334-357. (Pubitemid 34257478)